{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059749","form_type":"8-K","ticker":null,"cik":"0001463361","company_name":"Unity Biotechnology, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.504267+00:00","generated_at":"2026-06-02T00:39:32.614048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Unity Biotechnology Q1 net loss $5.8M, cash $38.3M; ASPIRE DME study on track","bullets":["Net loss $5.8M for Q1 2024 vs $5.3M in Q1 2023; cash & securities $38.3M as of Mar 31, 2024.","R&D expenses decreased to $3.7M from $5.8M due to completion of prior studies; focus on ASPIRE.","Phase 2b ASPIRE study for UBX1325 in DME upsized to 50 patients, extended to 36 weeks; 24-week data expected Q1 2025, 36-week data Q2 2025.","Cash runway sufficient into Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059749","json":"https://secwatch.observer/filing/0000950170-24-059749.json","markdown":"https://secwatch.observer/filing/0000950170-24-059749.md","text":"https://secwatch.observer/filing/0000950170-24-059749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/0000950170-24-059749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/ubx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:39:32.614048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1cf20dac68e971717c115ba00b03a0c0fe7e788","claim":"Unity Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/0000950170-24-059749-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}